Initial Statement of Beneficial Ownership (3)
15 Marzo 2019 - 9:16PM
Edgar (US Regulatory)
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Hurley Ariel
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/6/2019
|
3. Issuer Name
and
Ticker or Trading Symbol
Blueprint Medicines Corp [BPMC]
|
|
(Last)
(First)
(Middle)
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Principal Accounting Officer /
|
|
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Stock Option (Right to Buy)
|
(1)
|
10/8/2024
|
Common Stock
|
17994
|
$1.87
|
D
|
|
|
Stock Option (Right to Buy)
|
(2)
|
2/10/2025
|
Common Stock
|
5454
|
$8.8
|
D
|
|
|
Stock Option (Right to Buy)
|
(3)
|
2/3/2026
|
Common Stock
|
5000
|
$15.01
|
D
|
|
|
Stock Option (Right to Buy)
|
(4)
|
2/16/2027
|
Common Stock
|
9000
|
$36.05
|
D
|
|
|
Stock Option (Right to Buy)
|
(5)
|
2/16/2028
|
Common Stock
|
12000
|
$81.44
|
D
|
|
|
Stock Option (Right to Buy)
|
(6)
|
3/1/2029
|
Common Stock
|
11399
|
$86.6
|
D
|
|
|
Restricted Stock Units
|
(7)
|
(7)
|
Common Stock
|
3069
|
(8)
|
D
|
|
|
Explanation of Responses:
|
|
(1)
|
The Reporting Person was granted an option to purchase 20,909 shares of the Issuer's common stock on October 8, 2014. 2,915 shares underlying the option were previously exercised and sold by the Reporting Person. This option vested with respect to 25% of the shares underlying the option on September 15, 2015 and vests as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(2)
|
This option vested with respect to 1/48th of the shares underlying the option on March 10, 2015 and as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(3)
|
This option vested with respect to 1/48th of the shares underlying the option on March 3, 2016 and as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(4)
|
This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(5)
|
This option vested with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(6)
|
This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter.
|
|
(7)
|
The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023.
|
|
(8)
|
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
|
Remarks:
Exhibit 24 - Limited Power of Attorney
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Hurley Ariel
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE, MA 02139
|
|
|
Principal Accounting Officer
|
|
Signatures
|
|
/s/ Christopher Frankenfield, Attorney-in-Fact
|
|
3/15/2019
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Blueprint Medicines (NASDAQ:BPMC)
Storico
Da Set 2023 a Set 2024
